Skip to main content

Apixaban versus Aspirin for Embolic Stroke of Undetermined Source.

NEJM evidence

Authors: Tobias Geisler, Timea Keller, Peter Martus, Khouloud Poli, Lina Maria Serna-Higuita, Juergen Schreieck, Meinrad Gawaz, Johannes Tünnerhoff, Paula Bombach, Thomas Nägele, Uwe Klose, Parwez Aidery, Patrick Groga-Bada, Andrea Kraft, Frank Hoffmann, Carsten Hobohm, Katrin Naupold, Ludwig Niehaus, Marc Wolf, Hansjörg Bäzner, Jan Liman, Rolf Wachter, Hubert Kimmig, Werner Jung, Roman Huber, Regina Feurer, Alfred Lindner, Katharina Althaus, Felix J Bode, Gabor C Petzold, Thanh N Nguyen, Brian Mac Grory, Matthew Schrag, Jan C Purrucker, Christine S Zuern, Ulf Ziemann, Sven Poli

Apixaban versus Aspirin for Embolic StrokeIn a trial of 352 patients with embolic stroke of undetermined source, 5 mg of apixaban administered twice daily was compared with 100 mg of aspirin administered once daily for the prevention of recurrent ischemic strokes. At 12 months, 13.6% of patients given apixaban had new ischemic lesions on magnetic resonance imaging compared with 16.0% of patients given aspirin, and the rates of clinically relevant bleeding were also comparable.

PMID: 38320511

Participating cluster members